Five-Year Outcomes of the Early-Generation Intrepid Transapical Transcatheter Mitral Valve Replacement System.

Tang, GHL.; Rajagopal, V.; Sorajja, P.; Bajwa, T.; Gooley, R.; Walton, A.; Modine, T.; Ng, MK.; Williams, MR.; Zajarias, A.; Hildick-Smith, D.; Tchetche, D.; Spargias, K.; Rajani, R.; Bapat, VN.; De Backer, O.; Blackman, D.; McCarthy, P.; Laine, M.; Jain, R.; Martin, R.; Thaden, JJ.; Marka, NA.; Mack, M.; Adams, DH.; Leon, MB.; Reardon, MJ.

Five-Year Outcomes of the Early-Generation Intrepid Transapical Transcatheter Mitral Valve Replacement System.

All Authors

Tang, GHL.

Rajagopal, V.

Sorajja, P.

Bajwa, T.

Gooley, R.

Walton, A.

Modine, T.

Ng, MK.

Williams, MR.

Zajarias, A.

Show 10 more

LTHT Author

Blackman, Daniel

LTHT Department

Cardio-Respiratory
Cardiology

Publication Date

2025

Item Type

Journal Article

Abstract

BACKGROUND: Transcatheter mitral valve replacement (TMVR) offers a potential treatment option for select patients with mitral regurgitation (MR) deemed unsuitable for surgery or transcatheter repair, but data is limited on long-term durability and performance. AIMS: We evaluated 5-year outcomes from the global Pilot study (NCT02322840) with the Intrepid transapical (TA) TMVR system. METHODS: This multicenter, single-arm study evaluated the early-generation Intrepid TA system in patients with symptomatic >= moderate-severe MR at high risk for mitral valve (MV) surgery. Echocardiograms and clinical events were independently adjudicated, and patients were followed through 5 years. RESULTS: Ninety-five patients were enrolled at 21 sites between 2015 and 2019. Mean age was 74.0+/-9.2 years, 43.2% female, mean STS-PROM 6.5+/-4.8%, 57.9% had prior heart failure hospitalization (HFH), and 88.4% were in NYHA Class III/IV. Secondary MR was present in 78.7%, and 76.6% had a left ventricular ejection fraction <=50%. Through 5 years, all-cause mortality was 66.7% and HFH 55.4%, with one 30-day MV reintervention (1.1%). Hemodynamic valve deterioration occurred in 1.4%, median MV mean gradient remained stable at 3.6 mmHg (Q1, Q3: 3.0, 4.8 mmHg), with <= mild MR in 100% of patients, and none had paravalvular leak. NYHA Class I/II was maintained at 84.6%. CONCLUSIONS: In this 5-year follow-up of the early generation Intrepid TA TMVR system, we observed sustained MR reduction, durable hemodynamic valve performance, and improved functional status among survivors. The APOLLO (NCT03242642) and APOLLO-EU (NCT05496998) trials using the transfemoral system will determine the role of TMVR in managing this high-risk patient population.